ArticleCell communication and signaling : CCS2026
Piezo1 specific deletion in endothelial cell protects the progression of pulmonary fibrosis in mice.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundPiezo1, a mechanosensitive cation channel, plays a pivotal role in the pathogenesis of fibrosis by promoting intracellular calcium ion (Ca2+) influx and activating the calcium-dependent cysteine protease calpain. Pulmonary fibrosis (PF) is a progressive and often incurable disease, with current treatment strategies primarily relying on antifibrotic agents to slow disease progression. Accumulating evidence suggests that interdiction of Piezo1-induced Ca2+ signaling may suppress epithelial–mesenchymal transition (EMT) and modulate myofibroblast activation, thereby ameliorating PF. However, whether endothelial Piezo1 contributes to PF and the underlying mechanisms remain elusive.
objectivesThis study aims to investigate the role of endothelial Piezo1 in mediating the development of PF.
methodsA murine model of PF was established using bleomycin (BLM). Mice were sacrificed at 14 and 21 days post-administration. To investigate the role of Piezo1 in mediating endothelial–mesenchymal transition (EndMT) during PF, endothelial cell-specific Piezo1 knockout mice were generated. In parallel, in vitro experiments were conducted in which mesenchymal transition was induced by TGF-β1, followed by treatment with the Piezo1 activator Yoda1, the inhibitor GsMTx4 (a spider-venom peptide that blocks cationic mechanosensitive channels), and Piezo1-targeting siRNA to further validate the functional role of Piezo1.
resultsIn this study, we found that endothelial-specific deletion of Piezo1 (Piezo1ΔCDH5) in a BLM-induced PF mouse model effectively alleviates lung injury by reducing fibrotic lesions. In both in vivo and in vitro experiments, endothelial Piezo1 knockout significantly inhibited EndMT. Phenotypically, Piezo1ΔCDH5 mice exhibited markedly reduced PF and inflammation. Mechanistically, endothelial Piezo1 senses mechanical cues within the pulmonary microenvironment and opens to elicit Ca2+ influx. The resultant rise in intracellular Ca2+ activates calpain, which subsequently amplifies p38 and ERK phosphorylation, thereby driving EndMT and contributing to PF.
conclusionsOur findings demonstrate that Piezo1 regulates the p38/ERK-MAPK signaling pathway via the Ca2+/calpain axis to inhibit EndMT, thereby ameliorating PF. These results suggest that Piezo1 may serve as a potential therapeutic target for slowing the progression of PF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.